Clearmind Medicine Files International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Rhea-AI Summary

Clearmind Medicine (Nasdaq: CMND) has filed an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy using MEAI and Palmitoylethanolamide (PEA). The therapy targets obesity and metabolic dysfunction-associated steatotic liver disease (MASLD).

The company is developing this treatment in collaboration with SciSparc Ltd. (Nasdaq: SPRC). The therapy aims to address significant global health challenges, with obesity affecting over 890 million people worldwide and non-alcoholic fatty liver disease (NAFLD) impacting more than 30% of the global adult population.

Positive

• Filing of international patent application strengthens intellectual property portfolio
• Collaboration with SciSparc Ltd. enhances development capabilities
• Targets two major global health markets with limited treatment options
• Leverages unique properties of MEAI combined with PEA's anti-inflammatory benefits

Negative

• Early-stage development with no clinical efficacy data presented
• Patent approval not guaranteed
• Faces competition in crowded obesity treatment market

Insights

Biotech Patent Strategist

Clearmind's new patent filing strengthens their IP portfolio for MEAI combination therapy targeting major metabolic disorders with significant market potential.

Clearmind Medicine has made a strategic intellectual property move by filing an international PCT patent application for their MEAI and PEA combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). This filing provides potential patent protection across multiple territories simultaneously, a crucial step for any biotech aiming to commercialize novel therapies.

The company is targeting two massive markets with significant unmet needs. Obesity affects over 890 million people globally, while fatty liver disease impacts more than 30% of the global adult population. The current treatment landscape for both conditions remains limited, creating substantial market opportunities for effective therapies.

What makes this application particularly interesting is the combination approach. MEAI (5-methoxy-2-aminoindane) is a psychedelic-derived compound, while Palmitoylethanolamide (PEA) has established anti-inflammatory and neuroprotective properties. This strategic pairing could potentially address both the neurological and inflammatory components of metabolic disorders.

The collaboration with SciSparc Ltd. provides additional validation and potentially shared development resources. While still early-stage, this patent filing represents a crucial milestone in securing market exclusivity for what could become a significant therapeutic option in the metabolic disease space.

Pharmaceutical Development Expert

This patent application marks an important expansion of Clearmind's developmental pipeline beyond the typical mental health applications of psychedelic-derived compounds. The combination of MEAI with PEA represents an innovative approach to treating metabolic disorders by potentially addressing both neurological reward pathways and inflammatory processes.

What's notable is the company's strategic focus on repurposing and combining compounds with established safety profiles. PEA has been studied extensively for its anti-inflammatory properties, while MEAI is Clearmind's lead compound already being investigated for alcohol use disorder. This approach could potentially streamline the regulatory pathway compared to entirely novel molecules.

The timing is opportune given the recent explosion of interest in GLP-1 agonists for weight management. However, those medications come with limitations including cost, side effects, and limited efficacy for some patients. A psychedelic-derived alternative could offer a differentiated mechanism of action that might address patients who don't respond to current therapies.

While still very early in development (likely pre-clinical stage based on the disclosure), this represents a calculated expansion into high-value therapeutic areas that complement Clearmind's existing development programs. The PCT filing gives the company approximately 30 months to refine their clinical strategy before needing to commit to specific national phase entries, balancing IP protection with development flexibility.

Vancouver, Canada, July 30, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the filing of a new international patent application under the Patent Cooperation Treaty (PCT). The application covers its innovative combination therapy of MEAI (5-methoxy-2-aminoindane and N-Acylethanolamines) and Palmitoylethanolamide (PEA).

This proprietary combination is designed to address two significant global health challenges: obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). According to the World Health Organization, obesity affects over 890 million people worldwide and is a leading risk factor for a range of chronic conditions. Meanwhile, non-alcoholic fatty liver disease (NAFLD), which is closely linked to metabolic disorders and poor long-term outcomes, is estimated to impact more than 30% of the global adult population. Despite the scale of these problems, treatment options remain limited.

The Company believes that its novel approach has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA. This patent filing is part of Clearmind’s ongoing collaboration with SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage specialty pharmaceutical company developing therapies for central nervous system disorders.

“Our goal is to bring meaningful innovation to areas with high unmet medical need,” said Dr. Adi Zuloff-Shani, CEO of Clearmind. “This patent filing reflects our commitment to developing novel, science-backed treatments that can potentially improve the lives of millions struggling with obesity and fatty liver disease.”

About Clearmind Medicine Inc.

Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

The Company’s intellectual portfolio currently consists of nineteen patent families including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND" and the Frankfurt Stock Exchange under the symbol “CWY0.”

For further information visit: https://www.clearmindmedicine.com or contact:

Investor Relations
invest@clearmindmedicine.com

Telephone: (604) 260-1566
US: CMND@crescendo-ir.com

General Inquiries
Info@Clearmindmedicine.com
www.Clearmindmedicine.com

Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses its belief that its novel approach of the combination therapy of MEAI and PEA has the potential to offer a safe and effective therapeutic alternative, its goal to to bring meaningful innovation to areas with high unmet medical need and its commitment to developing novel, science-backed treatments that can potentially improve the lives of millions struggling with obesity and fatty liver disease.  The Company cannot assure that any patent will issue as a result of a pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2024 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.

FAQ

What is the new patent application filed by Clearmind Medicine (CMND)?

Clearmind Medicine filed an international PCT patent application for a combination therapy using MEAI and Palmitoylethanolamide (PEA) targeting obesity and fatty liver disease.

What medical conditions does Clearmind Medicine's (CMND) new therapy target?

The therapy targets two conditions: obesity, which affects over 890 million people worldwide, and metabolic dysfunction-associated steatotic liver disease (MASLD), which impacts more than 30% of global adult population.

Who is Clearmind Medicine (CMND) collaborating with on this treatment?

Clearmind Medicine is collaborating with SciSparc Ltd. (Nasdaq: SPRC), a clinical-stage specialty pharmaceutical company that develops therapies for central nervous system disorders.

What is the market potential for Clearmind Medicine's (CMND) new therapy?

The therapy addresses substantial markets, targeting conditions that affect over 890 million people with obesity and more than 30% of global adults with fatty liver disease, both areas with limited treatment options.

What are the key compounds in Clearmind Medicine's (CMND) new combination therapy?

The therapy combines MEAI (5-methoxy-2-aminoindane and N-Acylethanolamines) with Palmitoylethanolamide (PEA), leveraging MEAI's pharmacological profile and PEA's anti-inflammatory properties.